| Literature DB >> 29474375 |
Luiza Almeida Figueiredo1, Thais Fuscaldi Rebouças1, Sebastião Rodrigo Ferreira1, Gabriela Flavia Rodrigues-Luiz1, Rodrigo Cambraia Miranda2, Ricardo Nascimento Araujo1, Ricardo Toshio Fujiwara1.
Abstract
While diseases caused by nematodes remains a considerable drawback for the livestock, agriculture and public health, anthelmintics drug resistance has been observed over the past years and is a major concern for parasite control. Ivermectin, initially considered as a highly potent drug, currently presents a reduced anti-helminthic efficacy, which is influenced by expression of several ATP-binding cassette transporters (ABC), among them the P-glycoproteins (Pgps). Here we present some evidences of Pgps dominance during Ivermectin resistance/susceptibility using Pgps double silencing in C. elegans and the phylogenetic relationship of Pgps among nematodes, which strengthen the use of this model for study of drug resistance in nematodes. Firstly, we evaluated the quantitative gene expression of 12 out the 15 known Pgps from resistant and WT strains of C. elegans, we demonstrated the upregulation of Pgps 12 and 13 and downregulation of all remaining Pgps in ivermectin resistant strain. By using an RNAi loss-of-function approach we observed that Pgp 12 gene silencing reverts the resistance phenotype to ivermectin, while Pgp 4 gene silencing does not alter the resistance phenotype but induces a resistance in wild type strain. Interestingly, the dual silencing of Pgp 12 and Pgp 4 expression demonstrates the dominance of phenotype promoted by Pgp 12 silencing. Finally, in silico analysis reveals a close relationship between Pgps from C. elegans and several nematodes parasites. Taken together, our results indicate that Pgp 12 is crucial for the resistance to ivermectin and thus a good candidate for further studies aiming to develop specific inhibitors to this transporter, allowing the continuous use of ivermectin to control the burden on animal and human health inflicted by nematode parasites globally.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29474375 PMCID: PMC5825046 DOI: 10.1371/journal.pone.0192995
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers and sequence information.
| Genes | Primers | Sequences 5`→ 3` | Product lenght | Sequence confirmation—PCR products |
|---|---|---|---|---|
| Pgp 1 | Foward / Reverse | 160pb | ||
| Pgp 2 | Foward / Reverse | 150pb | ||
| Pgp 3 | Foward / Reverse | 154pb | ||
| Pgp 4 | Foward / Reverse | 153pb | ||
| Pgp 5 | Foward / Reverse | 156pb | ||
| Pgp 7 | Foward / Reverse | 101pb | ||
| Pgp 8 | Foward / Reverse | 149pb | ||
| Pgp 9 | Foward / Reverse | 118pb | ||
| Pgp 10 | Foward / Reverse | 102pb | ||
| Pgp 11 | Foward / Reverse | 129pb | ||
| Pgp 12 | Foward / Reverse | 107pb | ||
| Pgp 13 | Foward / Reverse | 136pb | ||
| CDC-42 | Foward / Reverse | 111pb | ||
| PMP-3 | Foward / Reverse | 115pb |
Fig 1C. elegans Pgps genes profile using 2-ΔΔCt method.
Pgps gene expression for WT strains are represented by dashed line. P values were obtained with One sample t test, comparing sample value to WT expression reference value.
Fig 2Evaluation of RNAi-mediated impairment of Pgp 12 expression in the WT and IVR30 strain.
(A) Percentage of L3 paralysis after 48 hours of ivermectin exposure for groups Pgp 12 silenced [RNAi+], Pgp 12 non silenced [RNAi-] and negative control [CT], cultured only in M9 medium and not exposed to ivermectin treatment. (B) Assessment L3 viability cell using propidium iodide marker after 48 hours ivermectin exposure in Pgp 12 silenced [RNAi+] and Pgp 12 non silenced [RNAi-] groups. P value refers to one-way ANOVA test with Turkey’s multiple comparisons test.
Fig 3Evaluation of RNAi-mediated impairment of Pgp 4 expression in the WT and IVR30 strain.
(A) Percentage of L3 paralysis after 48 hours of ivermectin exposure for groups Pgp 4 silenced [RNAi+], Pgp 4 non silenced [RNAi-] and negative control [CT], cultured only in M9 medium and not exposed to ivermectin treatment. (B) Assessment of L3 viability cell using propidium iodide marker after 48 hours ivermectin exposure in Pgp 4 silenced [RNAi+] and Pgp 4 non silenced [RNAi-] groups. P value refers to one-way ANOVA test with Turkey’s multiple comparisons test.
Fig 4Evaluation of RNAi-mediated impairment of Pgp 4 and 12 expression in the WT and IVR30 strain.
(A) Percentage of L3 paralysis percentage after 48 hours ivermectin exposure for groups Pgps 4 and 12 silenced [RNAi+], Pgps 4 and 12 non silenced [RNAi-] and negative control [CT], cultured only in M9 medium and not exposed to ivermectin treatment. (B) Assessement of L3 viability cell using propidium iodide marker after 48 hours ivermectin exposure in Pgps 4 and 12 silenced [RNAi+] and Pgps 4 and 12 non silenced [RNAi-] groups. P value refers to one-way ANOVA test with Turkey’s multiple comparisons test.
Fig 5In silico analysis revealing a close relationship between Pgps from C. elegans and nematodes parasites represented.
As follow: Ascaris suum (A), Brugia malayi (B), Cooperia oncophora (C), Haemonchus contortus (H), Loa loa (L), Onchocerca volvulus (O), Parascaris equorum (P), Strongyloides ratti (S), Trichuris trichiura (T), Wuchereria bancrofti (W), C. brenneri (1), C. briggsae (2), C. remanei (4), Pgp 4 of C. elegans (Δ), Pgp 12 of C. elegans (•), all remaining Pgps from C. elegans (2).